On July 23 and 24, the Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) met to consider whether a set of peptides should be added to the 503A Bulks List, which would permit licensed compounding pharmacies to legally make these drugs by physician prescription.

In a reversal of the committee’s past stance, PCAC voted to add six peptides–BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax to the 503A list. Use of these and many other peptide agents has risen rapidly over the last few years, despite existing in a legal and regulatory gray zone.

Advocates for peptide therapies contend that in the absence of clear FDA rules permitting compounding pharmacies to make them, patients are turning to highly questionable and potentially dangerous online sources of peptides.

The PCAC recommendations are just that: recommendations, not law. FDA can still opt against adoption of the committee’s suggestions. It remains to be seen whether the agency will, in fact, add the six aforementioned peptides to the 503A list. Still, the PCAC vote is being hailed as a major departure from FDA’s previously negative stance, and as a significant victory for health freedom and individual choice.

Once you decide a compound is acceptable, who’s accountable for how it’s actually used?

I delivered public comment during the Open Public Hearing portion of the PCAC meeting, speaking for a few minutes as a clinician and the founder of PepMD, an independent standards body developing the credentialing and trust infrastructure for peptide medicine.

My role wasn’t to argue for or against any specific peptide. It was to make one point: whichever way the committee voted, the infrastructure around peptide medicine isn’t adequate to generate the kind of evidence this committee will need in future reviews.

My biggest takeaway from the meeting was that the vote settles far less than the reactions to it would suggest.

Whichever peptides move forward, none of the harder questions get answered by a committee. These questions include: Who’s qualified to prescribe peptides? How are these substances sourced? Who, if anyone, is tracking what actually happens to patients who use them?

The vote is merely advisory, and formal rule-making still has to follow, which typically takes well over a year.

Even the strongest material submitted to PCAC was largely retrospective, assembled after the fact for a single hearing. That isn’t a knock on the people who did that work. Rather, it’s evidence that the field has no continuous system for generating evidence, which is exactly the gap I came to describe.

Surprises & Misconceptions

The most surprising thing I heard during the meeting was how much human data has actually surfaced on peptides, given how often we hear the hackneyed refrain that, “there’s no human evidence.”

The more accurate picture is that the evidence isn’t absent, but it is fragmented, scattered across submissions and registries and retrospective analyses rather than generated in a structured way. That distinction matters, and it changes how we think about the problem. It’s less that these compounds are unstudied, and more that there’s no one whose job it is to study them properly.

There were also a few misconceptions discussed during the meeting that would benefit from clarification.

The first is the idea that a favorable committee vote makes these peptides legal to compound right away. It doesn’t. The vote is merely advisory, and formal rule-making still has to follow, which typically takes well over a year.

Another misconception is the one I care about most, which is the assumption that being legally authorized to prescribe something is the same as being qualified to prescribe it. In peptide medicine, those two positions have come apart, and most people outside the field don’t realize it.

What FDA Does—and Doesn’t—Understand

Based on what I heard at the committee meeting, the FDA understands the evidence framework it’s built to apply, and it takes the safety questions seriously, which it should. The committee process is genuinely trying to responsibly weigh incomplete information.

The harder challenge isn’t in comprehension, but in the fact that that the FDA’s available tools (a bulks-list decision, a safety-and-efficacy review) aren’t designed to address the parts of the problem that live outside the specific benefits and risks of a particular peptide molecule itself. What I mean here are the issues around prescriber qualification, sourcing quality, and outcomes tracking. Those aren’t really the FDA’s levers to pull.

Peptide medicine is going to be one of the defining areas of healthcare this decade. The open question is, what kind of field it becomes: something rigorous and trustworthy, or a large market that never built standards underneath itself?

Overwhelmingly, I saw that the area of real-world outcomes is where the FDA still needs more information. Right now, there’s very little structured data on what actually happens to the large number of patients already using these compounds.

Regulators are being asked to make decisions in a near-vacuum of the exact information that would make those decisions easier. That vacuum exists because no one is systematically collecting it. That’s not a gap that regulations alone can close. It’s an infrastructure gap.

What PCAC Says About the Next Five Years

Peptide medicine is going to be one of the defining areas of healthcare this decade. That part isn’t really in question anymore. The open question is, what kind of field it becomes: something rigorous and trustworthy, or a large market that never built standards underneath itself?

The information shared at the FDA PCAC meeting made it clear that the science and the demand are already here. What’s missing is the connective tissue: credentialing, verification, and real research. The next five years will be defined by whether that infrastructure gets built or not.

In the future, I think the July 2026 meeting may be remembered as the point where the conversation on peptides started to shift from the molecules to the systems around them. For years, the entire debate has been substance by substance. Is this one safe? Is this one effective?

At the meeting, you could feel the bigger question pressing in: once you decide a compound is acceptable, who’s accountable for how it’s actually used? That’s a more mature question.

The most significant outcome of the PCAC meeting is not the committee’s votes on six specific peptides. It’s that the field of peptide medicine is moving in the direction toward tackling these broader issues.

END

Karthik Achari DNP-FNP, is the founder of PepMD, an independent standards body developing the credentialing and trust infrastructure for peptide medicine. PepMD is the first organization it is aware of to bring clinician credentialing, pharmacy recognition, and research site authorization together under a single standard. A clinician by training, Achari attended Bradley University’s Doctor of Nursing Practice / Family Nurse Practitioner program. Modeled in part after established accreditation systems like The Joint Commission, PepMD credentials clinicians, recognizes pharmacies, and authorizes research sites. PepMD was founded in January 2026 to address the rapid growth of peptide medicine without the infrastructure needed to support it.